These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 19183154)
41. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations? Sandborn WJ J Clin Gastroenterol; 2008 Apr; 42(4):338-44. PubMed ID: 18277908 [TBL] [Abstract][Full Text] [Related]
42. Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine. Deng X; Tolstanova G; Khomenko T; Chen L; Tarnawski A; Szabo S; Sandor Z J Pharmacol Exp Ther; 2009 Dec; 331(3):1071-8. PubMed ID: 19762547 [TBL] [Abstract][Full Text] [Related]
43. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Weiss TW; Henderson SC; McHorney CA; Cramer JA Curr Med Res Opin; 2007 Sep; 23(9):2193-203. PubMed ID: 17686228 [TBL] [Abstract][Full Text] [Related]
44. A clinical trial on absorption and N-acetylation of oral and rectal mesalazine. Dilger K; Trenk D; Rössle M; Cap M; Zähringer A; Wacheck V; Remmler C; Cascorbi I; Kreisel W; Novacek G Eur J Clin Invest; 2007 Jul; 37(7):558-65. PubMed ID: 17576207 [TBL] [Abstract][Full Text] [Related]
45. Treatment Adherence in Patients with Ulcerative Colitis Is Dependent on the Formulation of 5-Aminosalicylic Acid. Nakagawa S; Okaniwa N; Mizuno M; Sugiyama T; Yamaguchi Y; Tamura Y; Izawa S; Hijikata Y; Ebi M; Ogasawara N; Funaki Y; Sasaki M; Kasugai K Digestion; 2019; 99(2):133-139. PubMed ID: 30179881 [TBL] [Abstract][Full Text] [Related]
46. Factors associated with low adherence to oral 5-aminosalicylic acid in patients with ulcerative colitis. Lee J; Jee SR; Kim HW; Baek DH; Song GA; Moon W; Park SJ; Kim HJ; Lee JH; Park JH; Kim TO; PLoS One; 2019; 14(3):e0214129. PubMed ID: 30901362 [TBL] [Abstract][Full Text] [Related]
47. Natural history of severe ulcerative colitis in a community-based health plan. Allison J; Herrinton LJ; Liu L; Yu J; Lowder J Clin Gastroenterol Hepatol; 2008 Sep; 6(9):999-1003. PubMed ID: 18774533 [TBL] [Abstract][Full Text] [Related]
48. Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England. Russo EA; Harris AW; Campbell S; Lindsay J; Hart A; Arebi N; Milestone A; Tsai HH; Walters J; Carpani M; Westaby D; Thillainayagam A; Bansi D; Ghosh S Aliment Pharmacol Ther; 2009 Feb; 29(3):308-14. PubMed ID: 19035973 [TBL] [Abstract][Full Text] [Related]
50. Treatment of ulcerative colitis from the patient's perspective: a survey of preferences and satisfaction with therapy. Gray JR; Leung E; Scales J Aliment Pharmacol Ther; 2009 May; 29(10):1114-20. PubMed ID: 19222412 [TBL] [Abstract][Full Text] [Related]
51. NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis. Hausmann M; Paul G; Menzel K; Brunner-Ploss R; Falk W; Schölmerich J; Herfarth H; Rogler G Z Gastroenterol; 2008 Mar; 46(3):259-65. PubMed ID: 18322880 [TBL] [Abstract][Full Text] [Related]
52. First-year treatment adherence among outpatients initiating antihypertensive medication in Korea: results of a retrospective claims review. Sung SK; Lee SG; Lee KS; Kim DS; Kim KH; Kim KY Clin Ther; 2009 Jun; 31(6):1309-20. PubMed ID: 19695396 [TBL] [Abstract][Full Text] [Related]
53. Real-World Prescription Pattern and Healthcare Cost Among Patients with Ulcerative Colitis in Japan: A Retrospective Claims Data Analysis. Miyazaki C; Sakashita T; Jung W; Kato S Adv Ther; 2021 May; 38(5):2229-2247. PubMed ID: 33515423 [TBL] [Abstract][Full Text] [Related]
54. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Karve S; Cleves MA; Helm M; Hudson TJ; West DS; Martin BC Curr Med Res Opin; 2009 Sep; 25(9):2303-10. PubMed ID: 19635045 [TBL] [Abstract][Full Text] [Related]
55. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Singh S; Kim J; Zhu W; Dulai PS; Sandborn WJ; Jairath V Aliment Pharmacol Ther; 2020 Aug; 52(3):481-491. PubMed ID: 32573825 [TBL] [Abstract][Full Text] [Related]
56. Serial changes of cytokines in active ulcerative colitis: effects of antibiotic combination therapy. Sato K; Chiba T; Ohkusa T Hepatogastroenterology; 2009; 56(93):1016-21. PubMed ID: 19760932 [TBL] [Abstract][Full Text] [Related]
57. Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Henker J; Müller S; Laass MW; Schreiner A; Schulze J Z Gastroenterol; 2008 Sep; 46(9):874-5. PubMed ID: 18810672 [TBL] [Abstract][Full Text] [Related]
58. Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation. Van Wijk BL; Klungel OH; Heerdink ER; de Boer A J Clin Epidemiol; 2006 Jan; 59(1):11-7. PubMed ID: 16360556 [TBL] [Abstract][Full Text] [Related]
59. Adherence to 5-aminosalicylic acid maintenance treatment in young people with ulcerative colitis: a retrospective cohort study in primary care. Jayasooriya N; Pollok RC; Blackwell J; Bottle A; Petersen I; Creese H; Saxena S; Br J Gen Pract; 2023 Nov; 73(736):e850-e857. PubMed ID: 37666511 [TBL] [Abstract][Full Text] [Related]
60. The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity. Clara I; Lix LM; Walker JR; Graff LA; Miller N; Rogala L; Rawsthorne P; Bernstein CN Am J Gastroenterol; 2009 Jul; 104(7):1754-63. PubMed ID: 19455122 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]